Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.

Nicholls, Stephen J; Nelson, Adam J.
Am J Cardiovasc Drugs; 19(4): 343-348, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30680652